Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis

Annals of Neurology

Volumn 84, Issue 3, 2018, Pages 386-400

  He, Dan ^a   Zhang, Han ^a   Xiao, Jun ^a   Zhang, Xiaofan ^a   Xie, Minjie ^a,b   Pan, Dengji ^a   Wang, Minghuan ^a   Luo, Xiang ^a   Bu, Bitao ^a   Zhang, Min ^a   Wang, Wei ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Key Laboratory of Neurological Disease of Education Committee of China   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CHOLINERGIC RECEPTOR ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FREUND ADJUVANT; HEPATITIS B VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; CHOLINERGIC RECEPTOR; VIRUS ANTIBODY;

ADJUVANT THERAPY; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INFANT; JAPANESE ENCEPHALITIS; MAJOR CLINICAL STUDY; MALE; MOUSE; MUSCLE STRENGTH; MYASTHENIA GRAVIS; NERVE ENDING; NEWBORN; NONHUMAN; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VACCINATION; ANIMAL; BLOOD; IMMUNOLOGY; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CHILD; COHORT STUDIES; ENCEPHALITIS, JAPANESE; HUMANS; MICE; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; VACCINATION; VACCINES, ATTENUATED;

EID: 85053855245     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.25267     Document Type: Article

References (64)

1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475–490.
2. Zhu WH, Lu JH, Lin J, et al. HLA-DQA1*03:02/DQB1*03:03:02 is strongly associated with susceptibility to childhood-onset ocular myasthenia gravis in Southern Han Chinese. J Neuroimmunol 2012;247:81–85.
3. Zhang X, Yang M, Xu J, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 2007;78:386–390.
4. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010;10:46.
5. Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology 2010;35:66–71.
6. Murai H, Yamashita N, Watanabe M, et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 2011;305:97–102.
7. Alshekhlee A, Miles JD, Katirji B, et al. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009;72:1548–1554.
8. Aguiar Ade A, Carvalho AF, Costa CM, et al. Myasthenia gravis in Ceara, Brazil: clinical and epidemiological aspects. Arq Neuropsiquiatr 2010;68:843–848.
9. Ashraf VV, Taly AB, Veerendrakumar M, Rao S. Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand 2006;114:119–123.
10. Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis 2011;2011:404101.
11. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579–601.
12. Fang F, Sveinsson O, Thormar G, et al. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med 2015;277:594–604.
13. Deitiker PR, Oshima M, Smith RG, et al. Association with HLA DQ of early onset myasthenia gravis in Southeast Texas region of the United States. Int J Immunogenet 2011;38:55–62.
14. Matsuki K, Juji T, Tokunaga K, et al. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 1990;86:392–399.
15. Shinomiya N, Nomura Y, Segawa M. A variant of childhood-onset myasthenia gravis: HLA typing and clinical characteristics in Japan. Clin Immunol 2004;110:154–158.
16. Chen WH, Chiu HC, Hseih RP. Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese. J Neurol Neurosurg Psychiatry 1993;56:382–385.
17. Hawkins BR, Ip MS, Lam KS, et al. HLA antigens and acetylcholine receptor antibody in the subclassification of myasthenia gravis in Hong Kong Chinese. J Neurol Neurosurg Psychiatry 1986;49:316–319.
18. Evoli A. Acquired myasthenia gravis in childhood. Curr Opin Neurol 2010;23:536–540.
19. McDade TW. Life history, maintenance, and the early origins of immune function. Am J Hum Biol 2005;17:81–94.
20. Cavalcante P, Maggi L, Colleoni L, et al. Inflammation and Epstein-Barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis. Autoimmune Dis 2011;2011:213092.
21. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010;67:726–738.
22. Jing F, Wei D, Wang D, et al. Lack of Epstein-Barr virus infection in Chinese myasthenia gravis patients. Acta Neurol Scand 2013;128:345–350.
23. Stubgen JP. Neuromuscular disorders associated with Hepatitis B vaccination. J Neurol Sci 2010;292:1–4.
24. Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005;38:235–245.
25. Nachamkin I, Shadomy SV, Moran AP, et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barre syndrome. J Infect Dis 2008;198:226–233.
26. Huzé C, Bauché S, Richard P, et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009;85:155–167.
27. Maselli RA, Ng JJ, Anderson JA, et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet 2009;46:203–208.
28. Selcen D, Juel VC, Hobson-Webb LD, et al. Myasthenic syndrome caused by plectinopathy. Neurology 2011;76:327–336.
29. Wargon I, Richard P, Kuntzer T, et al. Long-term follow-up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscul Disord 2012;22:318–324.
30. Losen M, Stassen MH, Martínez-Martínez P, et al. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 2005;128(pt 10):2327–2337.
31. Cufi P, Dragin N, Weiss JM, et al. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol 2013;73:281–293.
32. Gowing EC, McKown KM. Myasthenia gravis in a patient with pauciarticular juvenile chronic arthritis. J Clin Rheumatol 2002;8:269–272.
33. Man BL, Mok CC, Fu YP. Neuro-ophthalmologic manifestations of systemic lupus erythematosus: a systematic review. Int J Rheum Dis 2014;17:494–501.
34. Wang Q, Weng L, Tian X, et al. Effect of the methyltransferase domain of Japanese encephalitis virus NS5 on the polymerase activity. Biochim Biophys Acta 2012;1819:411–418.
35. Wang W, Chen YP, Wang ZK, et al. A cohort study on myasthenia gravis patients in China. Neurol Sci 2013;34:1759–1764.
36. Drachman DB, Kao L, Angus CW, Murphy A. Effect of myasthenic immunoglobulin on ACh receptors of cultured muscle. Trans Am Neurol Assoc 1977;102:96–100.
37. Howard FM Jr, Lennon VA, Finley J, et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987;505:526–538.
38. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004;10(12 suppl):S98–S109.
39. Erlanger TE, Weiss S, Keiser J, et al. Past, present, and future of Japanese encephalitis. Emerg Infect Dis 2009;15:1–7.
40. Fischer M, Lindsey N, Staples JE, et al. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59:1–27.
41. Mackenzie JS, Smith DW. Japanese encephalitis virus: geographic distribution, incidence, and spread of a virus with a propensity to emerge in new areas. Pers Med Virol 2006;16:201–268.
42. Yang D, Li XF, Ye Q, et al. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2. Vaccine 2014;32:2675–2681.
43. Wijesinghe PR, Abeysinghe MR, Yoksan S, et al. Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka. Vaccine 2014;32:4751–4757.
44. Wang HJ, Li XF, Ye Q, et al. Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice. Vaccine 2014;32:949–956.
45. Kumar R, Tripathi P, Rizvi A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 2009;360:1465–1466.
46. Liu Y, Lin H, Zhu Q, et al. Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Guangdong, China, 2005-2012. Vaccine 2014;32:1768–1773.
47. Japanese encephalitis: status of surveillance and immunization in Asia and the Western Pacific, 2012. Wkly Epidemiol Rec 2013;88:357–364.
48. Liu W, Clemens JD, Yang JY, Xu ZY. Immunization against Japanese encephalitis in China: a policy analysis. Vaccine 2006;24:5178–5182.
49. Huang LM, Lin TY, Chiu CH, et al. Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: randomized study in toddlers in Taiwan. Vaccine 2014;32:5363–5369.
50. Trent DW, Minor P, Jivapaisarnpong T, et al. WHO working group on the quality, safety and efficacy of Japanese encephalitis vaccines (live attenuated) for human use, Bangkok, Thailand, 21-23 February 2012. Biologicals 2013;41:450–457.
51. Appaiahgari MB, Vrati S. IMOJEV(®): a yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 2010;9:1371–1384.
52. Rowhani-Rahbar A, Fireman B, Lewis E, et al. Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr 2013;167:1111–1117.
53. Sarntivijai S, Xiang Z, Shedden KA, et al. Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. PLoS One 2012;7:e49941.
54. Romio S, Weibel D, Dieleman JP, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe. PLoS One 2014;9:e82222.
55. Sipilä JO, Soilu-Hänninen M. The incidence and triggers of adult-onset Guillain-Barré syndrome in southwestern Finland 2004-2013. Eur J Neurol 2015;22:292–298.
56. Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014;13:215–224.
57. Langer-Gould A, Qian L, Tartof SY, et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol 2014;71:1506–1513.
58. Pellegrino P, Carnovale C, Perrone V, et al. Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems. PLoS One 2013;8:e77766.
59. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012;7:e33536.
60. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012;7:e33723.
61. Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med Rev 2018;38:177–186.
62. Aissaoui A, Klingel-Schmitt I, Couderc J, et al. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis. Ann Neurol 1999;46:559–567.
63. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain 2008;131(pt 7):1940–1952.
64. Maurer M, Bougoin S, Feferman T, et al. IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis. Acta Neuropathol Commun 2015;3:1.